ArticleSurgical endoscopy2010
Treatment of ultralong-segment Barrett's using focal and balloon-based radiofrequency ablation.
Article in Surgical endoscopy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.The American journal of gastroenterology · 2011Pooled it
- Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.BMC gastroenterology · 2010Pooled it
- Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus.Gastrointestinal endoscopy · 2011Trial
- Risk factors of fever following endoscopic radiofrequency ablation for early esophageal squamous cell carcinoma and precancerous lesions.World journal of gastrointestinal surgery · 2025Article
- Radiofrequency ablation devices.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2017Article
- Clinical Outcomes Following Recurrence of Intestinal Metaplasia After Successful Treatment of Barrett's Esophagus With Radiofrequency Ablation.The American journal of gastroenterology · 2017Article
- Predictors for postoperative esophageal stricture after balloon-based radiofrequency ablation for early esophageal squamous neoplasia: a multicenter validation study.Therapeutic advances in gastroenterology · 2016Article
- Radiofrequency Ablation Versus Endoscopic Submucosal Dissection in Treating Large Early Esophageal Squamous Cell Neoplasia.Medicine · 2015Observational
- Emerging indications of endoscopic radiofrequency ablation.United European gastroenterology journal · 2015Review
- Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study.Surgical endoscopy · 2014Article
- Barrett's esophagus: review of diagnosis and treatment.Gastroenterology report · 2013Article
- Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.The American journal of gastroenterology · 2013Article
- Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia.Gastrointestinal endoscopy · 2012Article
- The cost effectiveness of radiofrequency ablation for Barrett's esophagus.Gastroenterology · 2012Article
- Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation.Gastroenterology · 2012Article
- Barrett's esophagus with high-grade dysplasia: focus on current treatment options.World journal of gastroenterology · 2011Review
- Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.World journal of gastrointestinal endoscopy · 2011Article
- Endoscopic management of Barrett esophagus.Nature reviews. Gastroenterology & hepatology · 2011Review
- Barrett's esophagus: endoscopic treatments II.Annals of the New York Academy of Sciences · 2011Article
- Ablative therapies for Barrett's esophagus.Current gastroenterology reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEndoscopic radiofrequency ablation (ERFA) is being evaluated as definitive treatment for patients with Barrett's esophagus (BE). Guidelines have yet to be developed for the application of this technology to patients with ultralong-segment BE (ULBE, > or = 8 cm). This study reports a single institution's experience with ERFA of ULBE.
methodsA retrospective review of patients with ULBE undergoing ERFA from August 2005 to February 2009 was conducted. The entire segment of intestinal metaplasia (IM) was treated at each session using balloon- and/or plate-based devices (BARRX Medical, Inc., Sunnyvale, CA). Retreatments, endoscopic mucosal resection (EMR), dilations, and biopsies were performed based on endoscopic findings. Surveillance was conducted according to standard guidelines.
resultsTwenty-five patients (22 male) with a median age of 66 years [interquartile range (IQR) 57-74 years] were included. The length of BE treated was 10 cm (median; IQR 8-12 cm). Intramucosal carcinoma (IMC) was present in 3 patients, 15 had high-grade dysplasia (HGD), 6 had low-grade dysplasia (LGD), and 1 had IM without dysplasia. Complications for all 25 patients included hemorrhage (n = 1), stricture (n = 2), and nausea and vomiting (n = 2). Time from the initial procedure was such that 15 patients had postablation biopsies at least once. One patient with biopsies elected to undergo esophagectomy. Of these patients, 78.5% (11/14) had complete response (CR; no residual IM), two patients regressed from HGD to IM, and one patient with IMC had residual HGD and was treated with repeat EMR. The number of ablations in this group was 2.5 (median, IQR 2-3) during a median follow-up time of 20.3 months (IQR 10.4-29.2 months).
conclusionERFA is safe and feasible in patients with ULBE and can be applied to the entire length of IM during one session. Eradication of BE can be achieved with few repeat ablations and continued, vigilant surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.